Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs

Glynne-Jones, R., Meadows, H.M., Lopes, A., Muirhead, R., Sebag-Montefiore, D. and Adams, R. ORCID: https://orcid.org/0000-0003-3915-7243 2020. Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs. Annals of Oncology 31 (11) , pp. 1587-1588. 10.1016/j.annonc.2020.08.2097

Full text not available from this repository.

Abstract

We thank Jones et al. 1 for their comments on our article in a recent issue of the Annals of Oncology highlighting the adverse effects of poor compliance to chemotherapy and chemoradiation in the ACT II trial. 2 The authors advocate both testing for dihydropyrimidine dehydrogenase (DPD) and using capecitabine as an alternative to 5-fluorouracil (5-FU) on the grounds that twice-daily oral administration allows early reduction or discontinuation of the drug if toxicity is observed. They suggest initial dose reductions may not be required. This highlights the dilemma between prioritising safety issues or effectiveness for DPD variants.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	Elsevier
ISSN:	0923-7534
Last Modified:	09 Nov 2022 10:54
URI:	https://orca.cardiff.ac.uk/id/eprint/141029

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item